Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

antibody

  • Radioimmunoscintigraphy and Pretreatment Dosimetry of <sup>131</sup>I-Omburtamab for Planning Treatment of Leptomeningeal Disease
    You have access
    Radioimmunoscintigraphy and Pretreatment Dosimetry of 131I-Omburtamab for Planning Treatment of Leptomeningeal Disease
    Neeta Pandit-Taskar, Milan Grkovski, Pat B. Zanzonico, Keith S. Pentlow, Shakeel Modak, Kim Kramer and John L. Humm
    Journal of Nuclear Medicine June 1, 2023, 64 (6) 946-950; DOI: https://doi.org/10.2967/jnumed.122.265131
  • You have access
    Antibody Engineering for Nuclear Imaging and Radioimmunotherapy
    Cindy Rodriguez, Samantha Delaney, Samantha M. Sarrett, Outi M. Keinänen and Brian M. Zeglis
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 1316-1322; DOI: https://doi.org/10.2967/jnumed.122.263861
  • 
<sup>89</sup>Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression
    You have access
    89Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression
    Kyung-Ho Jung, Jin Won Park, Jin Hee Lee, Seung Hwan Moon, Young Seok Cho and Kyung-Han Lee
    Journal of Nuclear Medicine May 10, 2021, 62 (5) 656-664; DOI: https://doi.org/10.2967/jnumed.120.250720
  • You have access
    Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody
    Jorge A. Carrasquillo, Bernard M. Fine, Neeta Pandit-Taskar, Steven M. Larson, Stephen E. Fleming, Josef J. Fox, Sarah M. Cheal, Joseph A. O’Donoghue, Shutian Ruan, Govind Ragupathi, Serge K. Lyashchenko, John L. Humm, Howard I. Scher, Mithat Gönen, Simon P. Williams, Daniel C. Danila and Michael J. Morris
    Journal of Nuclear Medicine November 1, 2019, 60 (11) 1517-1523; DOI: https://doi.org/10.2967/jnumed.118.222844
  • Open Access
    Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors
    C. Willemien Menke-van der Houven van Oordt, Adam McGeoch, Mats Bergstrom, Iain McSherry, Deborah A. Smith, Matthew Cleveland, Wasfi Al-Azzam, Liangfu Chen, Henk Verheul, Otto S. Hoekstra, Danielle J. Vugts, Immanuel Freedman, Marc Huisman, Chris Matheny, Guus van Dongen and Sean Zhang
    Journal of Nuclear Medicine July 1, 2019, 60 (7) 902-909; DOI: https://doi.org/10.2967/jnumed.118.214726
  • You have access
    Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer
    Joanne E. Mortimer, James R. Bading, Jinha M. Park, Paul H. Frankel, Mary I. Carroll, Tri T. Tran, Erasmus K. Poku, Russell C. Rockne, Andrew A. Raubitschek, John E. Shively and David M. Colcher
    Journal of Nuclear Medicine January 1, 2018, 59 (1) 38-43; DOI: https://doi.org/10.2967/jnumed.117.193888
  • You have access
    PET-Guided Evaluation and Optimization of Internalized Antibody–Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor
    Orit Jacobson, Qing Li, Haojun Chen, Gang Niu, Dale O. Kiesewetter, Lan Xu, Kimberly Cook, Gengcheng Yang, William Dall’Acqua, Ping Tsui, Li Peng and Xiaoyuan Chen
    Journal of Nuclear Medicine November 1, 2017, 58 (11) 1838-1844; DOI: https://doi.org/10.2967/jnumed.117.192245
  • You have access
    Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers
    Jimson W. D’Souza, Harvey Hensley, Mohan Doss, Charles Beigarten, Michael Torgov, Tove Olafsen, Jian Q. Yu and Matthew K. Robinson
    Journal of Nuclear Medicine January 1, 2017, 58 (1) 175-180; DOI: https://doi.org/10.2967/jnumed.116.178780
  • You have access
    Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine–Labeled CD30-Specific AC-10 Antibody
    Svetlana N. Rylova, Luigi Del Pozzo, Cathrin Klingeberg, Roswitha Tönnesmann, Anna L. Illert, Philipp T. Meyer, Helmut R. Maecke and Jason P. Holland
    Journal of Nuclear Medicine January 1, 2016, 57 (1) 96-102; DOI: https://doi.org/10.2967/jnumed.115.162735
  • You have access
    Three-Dimensional Histologic Validation of High-Resolution SPECT of Antibody Distributions Within Xenografts
    Woutjan Branderhorst, Erwin L.A. Blezer, Mischa Houtkamp, Ruud M. Ramakers, Jeroen H. van den Brakel, Henry Witteveen, Frans van der Have, Hugo A. Gratama van Andel, Brendan Vastenhouw, Chao Wu, Marijke Stigter-van Walsum, Guus A.M.S. van Dongen, Max A. Viergever, Wim K. Bleeker and Freek J. Beekman
    Journal of Nuclear Medicine May 1, 2014, 55 (5) 830-837; DOI: https://doi.org/10.2967/jnumed.113.125401

Pages

  • Next
  • 1
  • 2
SNMMI

© 2025 SNMMI

Powered by HighWire